



*TSX Venture Exchange: CCG  
FOR IMMEDIATE RELEASE*

## **CardioComm Solutions Inc. Announces Upgrade to GEMS™ Software System Including HL7 Interface**

**VICTORIA, B.C., December, 21 2004** – CardioComm Solutions Inc. (TSX-V:CCG) (the "Company", "CardioComm"), is pleased to report that it has launched GEMS™ 3.11, the latest upgrade for its ever popular cardiac software, including over 25 new features and upgrades.

The most significant new feature is an HL7 (Health Level 7) interface engine. HL7 is a standard that defines a common method of exchange, management and integration of data used to support clinical patient care. With HL7, GEMS™ can now readily send and receive information with other hospital based information systems, enhancing the efficiency of GEMS™ and enabling the outputs from GEMS™ to be captured in other integrating applications.

CardioComm's first application of its HL7 engine is with the Apollo Advance™ clinical data repository from U.S. based Lumedx Corporation. Involving a major medical center in the northeast, the integration with GEMS™ will allow clinicians to integrate electrophysiology, implant and pacing information with the rest of the cardiovascular medical record.

Lumedx serves more than 300 heart centers worldwide providing comprehensive access to diagnostic and therapeutic clinical data in more than 25 sub-specialty areas of cardiovascular medicine. Apollo Advance™ is the industry's premier cardiovascular clinical data repository and is designed to fulfill two primary goals: (1) provide a complete patient medical record integrating data, images & text and (2) maintain a warehouse of aggregated patient data for outcomes management.

“We are pleased to add the GEMS™ interface to our industry-leading library of integration tools. Information on demand is essential to maintaining best practice standards in cardiovascular care,” according to Chris Winquist, Vice President of Strategic Services for Lumedx.

Other key features in CardioComm GEMS™ 3.11 release include updated pacemaker and ICD device lists, new ECG editing tools, enhanced device implant records, new event monitor device drivers (supporting devices from Aerotel, Braemar, Integrated Medical Devices (IMD), and Lechnologies), expanded comments, and integrated PDF output for reports.

GEMS™ 3.11 will also enable users to modify field labels to match their preferred terminology, reducing the chances for ambiguity and error in clinical use.

### **About Lumedx Corporation**

During the past 15 years, Lumedx has assisted more than 300 heart centers worldwide in building powerful integrated solutions. As the No. 1 independent cardiovascular systems integrator, LUMEDX's software, services, and analytics help medical institutions enhance the quality of patient care, streamline workflow, increase patient volumes, reduce costs, and grow revenues.

### **About CardioComm Solutions Inc:**

CardioComm's patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (ECGs), for diagnosis and management of cardiac patients. The Company's products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time ECG viewer. CardioComm is the first company to provide a real-time means of viewing ECGs over a network (LAN, WAN or Internet). This tool enables ECGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global ECG Management System (GEMS™) and GlobalCardio™. CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors  
of CardioComm Solutions Inc.:

“Stephen Martin”

---

Stephen R. Martin, President & CEO

*For investor information, please  
contact:*

Derek Sutherland  
**(416) 832-0442**  
IR@CardioComm.com

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this release.